Clin2
NCT06766552Worth exploringNot yet recruiting

A study on vunakizumab for rheumatic diseases

Ankylosing Spondylitis (AS)Psoriatic Arthritis (PsA)Nr-axSpAPolymyalgia Rheumatica (PMR)Takayasu Arteritis (TAK)Giant Cell Arteritis (GCA)Behcet's DiseaseEnthesitis-related Arthritis

Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.

This study looks at how well vunakizumab works for people with certain inflammatory rheumatic conditions, like ankylosing spondylitis or psoriatic arthritis. It tracks symptoms, how the medicine is used, and any side effects over time.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
10,000 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You have a rheumatic autoimmune condition (like ankylosing spondylitis, psoriatic arthritis, or similar).
  • You are currently using or plan to start vunakizumab treatment.
  • You can come to follow-up visits as advised by your doctor.
  • You understand and sign a consent form to join the study.
  • Your doctor does not think you have any reason that would make it unsafe or hard for you to complete the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07451665Not yet recruiting· Phase 4
Testing two drugs for active Takayasu's arteritis

This study tests two new medications, vunakizumab and ivarmacitinib, for people with active Takayasu's arteritis (TAK) that is not fully controlled by standard treatments. The goal is to see if these drugs are safe and effective for reducing disease activity.

Beijing, Beijing Municipality
NCT07150000Recruiting
Rheumatic disease research study for patients and healthy volunteers

This study is for people with certain rheumatic conditions (like arthritis, lupus, or vasculitis) and for healthy volunteers. It aims to learn more about these diseases and improve how they are treated.

Bonn, North Rhine-Westphalia
NCT06526377Not yet recruiting· Phase 2
Vilamakitug for active axial spondyloarthritis

This study tests a new medication called vilamakitug for people with active axial spondyloarthritis. It aims to see if the drug can reduce pain and inflammation better than a placebo (a dummy treatment).

NCT06668181Recruiting· Phase 3
Study of bimekizumab for kids with certain types of juvenile arthritis

This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.

Calgary
NCT06770088Not yet recruiting· Phase 4
Vunakizumab for adults with spondyloarthritis

This trial tests a new biologic drug called Vunakizumab for adults with spondyloarthritis (a type of arthritis affecting the spine). It aims to see if the drug can help control symptoms and inflammation.

NCT06881290Recruiting· Phase 1
Vunakizumab for mild to moderate lupus

This trial tests a new drug called Vunakizumab for people with mild to moderate lupus that affects the skin or joints. It aims to see if adding this drug to your current treatment can help control symptoms better.

Beijing, Beijing Municipality

Hear when a new Psoriatic Arthritis (PsA) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.